Jazz Pharmaceuticals plc P/E Ratio

Jazz Pharmaceuticals plc posts a P/E ratio of 65.58. That is above the Healthcare sector average of 22.57. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a P/E ratio near 22.57 is typical. Jazz Pharmaceuticals plc's 65.58 is higher that level. That is roughly 190.5% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Jazz Pharmaceuticals plc's P/E ratio of 65.58 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for JAZZ's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.57), and (3) consistency with growth and profitability. This page covers the first two; Jazz Pharmaceuticals plc's other metric pages and overview cover the third.

Judging Jazz Pharmaceuticals plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in P/E ratio easier to interpret. Start with 65.58 here, then scan peer and history charts to see if the gap is persistent.